Immunotherapy in Head and Neck Squamous Cell Cancer

Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Denaro, Nerina, Merlano, Marco Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Otorhinolaryngology-Head and Neck Surgery 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222190/
https://www.ncbi.nlm.nih.gov/pubmed/29973040
http://dx.doi.org/10.21053/ceo.2018.00150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222190/
https://www.ncbi.nlm.nih.gov/pubmed/29973040
http://dx.doi.org/10.21053/ceo.2018.00150

Ejemplares similares